Publications by authors named "Keke Fei"

Claim this Profile
C
Characterization of a novel anti-PVRIG antibody with Fc-competent function that exerts strong antitumor effects via NK activation in preclinical models.
Hongyu Xue, Zhimin Zhang, Li Li, Chenjuan Zhu, Keke Fei, Feifei Wang

Cancer Immunol Immunother· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IBI379, a novel B cell maturation antigen/CD3 bispecific T-cell engager, displays high antitumor efficacy in preclinical models of multiple myeloma.
Keke Fei, Haiqing Ni, Mengjia Zhu, Zhihui Kuang, Min Wu, Feifei Wang

Cancer Lett· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
LcrQ Coordinates with the YopD-LcrH Complex To Repress Expression and Control Type III Secretion by Yersinia pseudotuberculosis.
Keke Fei, Huan Yan, Xiaoyan Zeng, Shaojia Huang, Wei Tang

mBio· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of the binding motif for the T3SS master regulator LcrF in Yersinia pseudotuberculosis.
Luyi Liu, Shaojia Huang, Keke Fei, Wei Zhou, Shiyun Chen

FEMS Microbiol Lett· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CpxR regulates the Rcs phosphorelay system in controlling the Ysc-Yop type III secretion system in .
Keke Fei, Hong-Jun Chao, Yangbo Hu, Matthew S Francis, Shiyun Chen

Microbiology (Reading)· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit.
Jie Wang, Keke Fei, Hua Jing, Zhihai Wu, Weiwei Wu

MAbs· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis